Table 1.
Demographic and Clinicopathological Characteristics of Patients with NSCLC.
| Variables | Overall (n=403) | PPR<1.21 (n=269) | PPR≥1.21 (n=134) | P-value |
|---|---|---|---|---|
| Gender, n (%) | 0.144 | |||
| Male | 226 (56.1%) | 144 (53.5%) | 82 (61.2%) | |
| Female | 177 (43.9%) | 125 (46.5%) | 52 (38.8%) | |
| Age(years), Median (IQR) | 62 (53-69) | 61 (53-67) | 63 (54-71) | 0.054 |
| Smoking, n (%) | 0.696 | |||
| Yes | 151 (37.5%) | 99 (36.8%) | 52 (38.8%) | |
| No | 252 (62.5%) | 170 (63.2%) | 82 (61.2%) | |
| Tumor size | 0.001 | |||
| ≤5cm | 356 (88.3%) | 248 (92.2%) | 108 (80.6%) | |
| >5cm | 47 (11.7%) | 21 (7.8%) | 26 (19.4%) | |
| pT, n (%) | 0.025 | |||
| ≤T2 | 342 (84.8%) | 237 (88.1%) | 105 (78.3%) | |
| T3 | 43 (10.7%) | 24 (8.9%) | 19 (14.2%) | |
| T4 | 18 (4.5%) | 8 (3.0%) | 10 (7.5%) | |
| pN, n (%) | <0.001 | |||
| Negative | 286 (71.0%) | 222 (82.5%) | 64 (47.8%) | |
| Positive | 117 (29.0%) | 47 (17.5%) | 70 (52.2%) | |
| TNM, n (%) | <0.001 | |||
| Ⅰ | 249 (61.8%) | 195 (72.5%) | 54 (40.3%) | |
| Ⅱ | 79 (19.6%) | 49 (18.2%) | 30 (22.4%) | |
| Ⅲ | 75 (18.6%) | 25 (9.3%) | 50 (37.3%) | |
| Microvascular invasion | 0.088 | |||
| Yes | 175 (43.4%) | 102 (37.9%) | 61 (45.5%) | |
| No | 228 (56.6%) | 167 (62.1%) | 73 (54.5%) | |
| Ki67 (%), Median (IQR) | 15 (5-40) | 10 (5-35) | 20 (10-50) | 0.004 |
| EGFR mutation, n (%) | 0.878 | |||
| Yes | 53 (13.1%) | 37 (13.8%) | 16 (11.9%) | |
| No | 33 (8.2%) | 22 (8.2%) | 11 (8.2%) | |
| NA | 317 (78.7%) | 210 (78.0%) | 107 (79.9%) | |
| ALK mutation, n (%) | 0.787 | |||
| Yes | 5 (1.2%) | 4 (1.5%) | 1 (0.7%) | |
| No | 81 (20.1%) | 55 (20.4%) | 26 (19.4%) | |
| NA | 317 (78.7%) | 210 (78.1%) | 107 (79.9%) | |
| Adjuvant Therapy*, n (%) | 0.074 | |||
| Yes | 137 (34.0%) | 83 (30.9%) | 54 (40.3%) | |
| No | 266 (66.0%) | 186 (69.1%) | 80 (59.7%) | |
| WBC(x109/L), Median (IQR) | 6.33 (5.36-7.88) | 6.39 (5.27-8.14) | 6.27 (5.46-7.41) | 0.146 |
Abbreviation: PPR, postoperative platelet/preoperative platelet ratio; IQR, interquartile range; TNM, Tumor Node Metastasis; EGFR, epidermal growth factor receptor; ALK, anaplastic Lymphoma kinase. * Adjuvant radiotherapy and/or adjuvant chemotherapy.